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FtDp-17t, this is the first example of the successful gen-
eration of iNs from skin cells retrieved post-mortem.
Keywords K298e MApt mutation · tauopathies · 
Human induced-neurons
Introduction
Frontotemporal lobar degeneration (FtLD) consists of a 
group of disorders that manifest as the result of an ini-
tial pathological damage of the frontal and temporal lobes 
of the cerebrum [2, 19, 21]. Hereditary forms represent 
20–30 % of all cases of FtLD and up to 15–20 % of 
these carry mutations in MAPT, the gene coding for the 
microtubule-associated protein tau [22]. patients carry-
ing MAPT mutations are characterized by filamentous and 
hyperphosphorylated tau inclusions in neuronal and glial 
Abstract Frontotemporal lobar degeneration (FtLD) 
consists of a group of neurodegenerative diseases char-
acterized by behavioural and executive impairment, lan-
guage disorders and motor dysfunction. About 20–30 % 
of cases are inherited in a dominant manner. Mutations in 
the microtubule-associated protein tau gene (MAPT) cause 
frontotemporal dementia and parkinsonism linked to chro-
mosome 17 (FtDp-17t). Here we report a novel MAPT 
mutation (K298e) in exon 10 in a patient with FtDp-17t. 
Neuropathological studies of post-mortem brain showed 
widespread neuronal loss and gliosis and abundant depo-
sition of hyperphosphorylated tau in neurons and glia. 
Molecular studies demonstrated that the K298e mutation 
affects both protein function and alternative mRNA splic-
ing. Fibroblasts from a skin biopsy of the proband taken at 
post-mortem were directly induced into neurons (iNs) and 
expressed both 3-repeat and 4-repeat tau isoforms. As well 
as contributing new knowledge on MApt mutations in 
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cells, causing neurodegeneration. In normal brain, tau 
promotes microtubule assembly and stabilization, and is 
involved in axonal transport [10]. In adult human brain six 
tau isoforms are produced by alternative mRNA splicing 
from a single gene located on chromosome 17 [7]. they 
differ by the presence of 29- or 58- amino acid inserts in 
the amino-terminal half of the protein, and by the pres-
ence of three (3R) or four (4R) repeats in the carboxyl-
terminal half. the repeats and some adjoining sequences 
constitute the microtubule-binding domains of tau [12]. 
MAPT mutations have their primary effect either at the 
protein level, reducing the ability of tau to interact with 
microtubules, or at the mRNA level, altering the balance 
between 3R and 4R tau isoforms [6, 10]. Here we report 
the identification and characterization of a novel MAPT 
mutation in exon 10, 892 AAA›GAA, leading to a change 
from lysine to glutamate at codon 298 (K298e). this 
mutation significantly reduced the ability of tau to pro-
mote microtubule assembly and altered exon 10 splicing 
by increasing the expression of 4R tau. In the proband’s 
brain, neuronal and glial 4R tau pathology was present. 
Moreover induced neurons (iNs) obtained via transcrip-
tion-factor mediated direct conversion from patient skin-
derived fibroblasts with the K298e mutation expressed 
both 3R and 4R tau isoforms. this expression pattern was 
similar to that of neurons from an age-matched control, 
but differed from that of neurons obtained from embryo-
derived human fibroblasts.
Materials and methods
Case report
the proband was referred at the age of 67 because of pro-
gressive gait difficulties and non-fluent aphasia. Her symp-
toms had rapidly progressed over the preceding 2 years. 
Her father had been diagnosed with Alzheimer’s disease 
in his 60 s and had died at the age of 67. the only living 
relative is the proband’s son who is currently asympto-
matic. the proband died at the age of 68 and her brain was 
donated to the Queen square Brain Bank for Neurological 
Disorders, UCL Institute of Neurology.
Genetic analyses
Genomic DNA was extracted from 5 ml of blood collected 
from the patient and it was analysed at the east Anglian 
Regional Molecular Genetics Laboratory, Addenbrooke’s 
Hospital, Cambridge UK. Fluorescence sequencing of 
exons 1–5, 7, 9–13 (including intronic boundaries) of 
MApt gene was performed.
purification of recombinant tau
the quick change lightning site-directed mutagenesis kit 
(stratagene, edinburgh, UK) was used to introduce the 
K298e mutation into the shortest 4R isoform (4R0N, t43) 
of human brain tau.
Wild-type, p301s and K298e mutant human tau cDNAs 
were subcloned into pRK172 and transformed into BL21 
(De3) E. coli, as described [8]. Briefly, following induction 
with 0.4 mM IptG, the cells were collected by centrifuga-
tion, the pellet was resuspended in 30 ml of 25 mM tris pH 
7.4, 10 mM eDtA, 0.1 mM Dtt, 0.1 mM pMsF and the 
cell suspension disrupted at 4 °C in a constant system cell 
disruptor. Recombinant tau protein was purified by anion-
exchange chromatography and dialysed overnight at 4 °C 
against 40 mM Hepes, pH 7.4, plus 0.1 mM Dtt.
Microtubule assembly assay
the ability of recombinant tau proteins to promote micro-
tubule assembly was monitored by turbidity, as described 
[8]. tubulin (Cytoskeleton Inc., Denver, CO, UsA) was 
dissolved in G-peM buffer (80 mM Na-pIpes pH 6.9, 
1 mM MgCl2, 1 mM eGtA, 1 mM Gtp) and mixed 
with 77.5 μl of G-peM. Wild-type or mutant tau was 
then added and the mixture was quickly transferred to a 
quartz cuvette. the final concentrations of both tubulin 
and tau were 1 mg/ml. polymerization of microtubules 
was monitored by measuring the absorbance at 350 nm 
at 37 °C over 10 min. All experiments were performed in 
triplicate.
Minigene transfection
A previously described [1] MAPT minigene construct 
encompassing exons 9–11 and flanking e10 intronic 
sequences in pcDNA3 was kindly provided by Dr R. 
Vuono, as was the construct with the I10+3 G>A intronic 
mutation. the quick change lightning site-directed 
mutagenesis kit was used to introduce the K298e muta-
tion in exon 10 of MAPT. Neural stem cells (NsCs) were 
obtained from human embryonic stem cells and maintained 
in a neural precursor stage in defined medium in the pres-
ence of 20 ng/ml of FGF2, as described [15, 24]. transient 
transfections were performed using Lipofectamine 2000, 
according to the manufacturer’s instructions (Invitrogen, 
eugene OR, UsA). Cells were plated into a six-well plate 
at a density of 2 × 105 cells/well and incubated in the 
absence of antibiotics for 24 h. For single transfections, 
2 μg of the wild-type or mutant minigene DNA was mixed 
with 10 μl Lipofectamine 2000 in Optimem medium (Invit-
rogen, eugene OR, UsA) and incubated for 20 min at room 
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temperature. For co-transfections, 1 μg of each construct 
(wild-type and mutant) was used. Cells were exposed to 
the transfection mixture for 5 h at 37 °C and 5 % CO2 and 
returned to their growing medium. to analyse minigene 
expression, cells were harvested 48 h after transfection.
RNA extraction and Rt-pCR
total RNA was extracted from NsCs with the RNeasy mini 
kit (Qiagen, Crawley, UK). RNA concentration and purity 
were estimated using spectrophotometry (absorbance at 
230, 260 and 280 nm). three-repeat and 4R tau mRNA 
expression was detected by Rt-pCR using the onestep Rt-
pCR kit (Qiagen, Crawley, UK) and the following primers: 
exon 9 forward 5′ CtCCAAAAtCAGGGGAtCGC 3′ and 
exon11 reverse 5′ tAtGAtGGAtGttGCCtAAtGAGCC 
3′. Bands corresponding to mRNAs with and without exon 
10 were separated by electrophoresis on 1 % agarose gels. 
the same method was used for Rt-pCR of RNA extracted 
from frontal cortex of the patient with the K298e mutation 
and of a control subject.
Human brain tissues
tissue from cerebral cortex of a patient with the I10+3 
G>A MApt mutation was obtained from the Brain Bank 
of the Indiana University Alzheimer Centre [26]. Frontal 
cortex from an age-matched control subject was obtained 
from the Cambridge Hospital Brain Bank. the work on 
human tissue was covered by Cambridge LReC ethical 
Table 1  Antibodies used in this study
Antibody epitope/antigen species Dilution source
At8 tau (phospho-ser202/ser205) Mouse 1:600 Autogen Bioclear, Wiltshire, UK
RD03 3-Repeat tau Mouse 1:2,000 Dr Rohan De silva/Millipore
RD04 4-Repeat tau Mouse 1:100 Dr Rohan De silva/Millipore
At100 tau (phospho ser212/thr214/t217) Mouse 1:200 Autogen Bioclear, Wiltshire, UK
Aβ β-amyloid protein (M0872) Mouse 1:100 DAKO, ely, UK
α-synuclein α-synuclein Mouse 1:75 Novocastra, peterborough, UK
p62 p62 lck ligand Mouse 1:100 BD transduction Labs, Oxford, UK
tDp-43 tar DNA-binding protein-43 Mouse 1:800 Abnova, taipei City, taiwan
GFAp Glial fibrillary acidic protein Rabbit 1:1 K DAKO, ely, Uk
Neurofilaments phosphorylated (sMI 31) and non- 
phosphorylated (sMI 32) neurofilaments
Mouse sMI 31—1:5,000
sMI 32—1:500
sternberger Monoclonals Inc, Baltimore, UsA
αB crystallin Novacastra Mouse 1:300 Novocastra, peterborough, UK
Fig. 1  Microtubule assem-
bly assay. polymerization of 
tubulin induced by wild-type 
tau, p301s tau and K298e tau. 
Microtubule assembly was 
monitored over time by optical 
density (absorbance 350 nm). 
the results are expressed as the 
means of three different experi-
ments
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approval (ref no 09/40). Neuropathological investigation 
was performed at the Queen square Brain Bank for Neuro-
logical Disorders, London. Handling of human tissue was 
according to the UK Human tissue Act 2006. Approval for 
“Generation of patient-specific stem cells for research in 
neurodegenerative disorders of the CNs” was granted by 
the Hertfordshire Research ethics Committee (ref no 09/
H0311/88).
Immunohistochemistry
Following fixation in 10 % buffered formalin, the left half 
of the proband’s brain was sliced in the coronal plane and 
blocks were selected for histological examination. the 
right half of the brain was sliced in the coronal plane, flash 
frozen and stored at −80 °C. paraffin-embedded sections 
(8 μm) from cortical, subcortical, brainstem and cerebel-
lar regions were stained using haematoxylin eosin (He) 
and Gallyas silver impregnation. Immunohistochemistry 
was performed using the antibodies listed in table 1. sec-
tions were deparaffinised using xylene and rehydrated 
using graded alcohols. endogenous peroxidase activity 
was blocked with methanol/0.3 % H2O2. Antigen retrieval 
was achieved by heating sections in a pressure cooker for 
10 min in citrate buffer (pH 6.0). For Aβ and α-synuclein 
immunohistochemistry, sections required pre-treatment 
with formic acid for 10 min prior to antigen retrieval. sec-
tions were incubated in dried milk solution (10 % in pBs, 
30 min) to block non-specific binding. primary antibod-
ies diluted in pBs were applied for 60 min at room tem-
perature, followed by either biotinylated anti-rabbit IgG or 
biotinylated anti-mouse IgG (1:200, 30 min; DAKO) and 
ABC complex (30 min; DAKO). the sections were devel-
oped with di-aminobenzidine/H2O2 and counterstained 
with He.
Neuronal loss and gliosis were assessed on He-stained 
sections and scored semi-quantitatively as follows: 
− = none; + = mild; ++ = moderate; +++ = severe. 
the frequency of tau-positive inclusions of different types 
was assessed using antibody At8 and scored semi-quan-
titatively: − = none; + = infrequent; ++ = moderate; 
+++ = frequent.
Immunocytochemistry
Cells were fixed with 4 % paraformaldehyde and pre-
incubated for 1 h in blocking solution (5 % normal goat 
serum, 0.02 % tween in pBs). primary antibodies (mono-
clonal 3R tau isoform 1:500, Millipore; monoclonal 4R 
tau isoform, 1:500 Millipore; polyclonal betaIIItubulin 
1:1,000, Covance) were incubated overnight at 4 °C. For 
3R and 4R tau immunofluorescence, cells were incubated 
with biotinylated secondary antibodies (1:250) for 2 h at 
room temperature and 1 h with fluorescent streptavidin 
(Alexa Invitrogen, 1:500). Anti rabbit fluorescent-conju-
gated secondary antibodies (Alexa, Invitrogen Molecular 
probes) diluted 1:1,000 were used for betaIIItubulin stain-
ing. Double-labelling immunofluorescence was performed 
by sequential incubation with the appropriate primary 
Fig. 2  Reverse transcription polymerase chain reaction (Rt-pCR) 
analysis of tau mRNA expression in human neural stem cells trans-
fected with a tau minigene and mRNA extracted from frontal cortex 
of the K298e patient. the tau minigene construct consisted of the 
pcDNA3 vector containing tau exons 9, 10 and 11, and the e10 flank-
ing intronic sequences of minimal length for correct splicing. the 
splicing patterns of MAPT exon 10 in minigene transfected human 
neural stem cells (NsCs) are shown. a Untransfected human NsCs 
expressed high levels of 3R tau mRNA and low levels of 4R tau 
mRNA (lane 1) similar to cells transfected with the empty pcDNA3 
vector (lane 2). transfection with the wild-type tau minigene did not 
change the ratio between the two mRNAs (lane 3), with the expres-
sion level of 3R tau mRNA remaining predominant. When human 
NsCs were transfected with the minigene carrying the +3 MAPT 
mutation, the mRNA level of 4R tau increased (lane 4) and this also 
occurred after transfection with the minigene carrying the K298e 
mutation (lane 5). Co-transfection of wild-type and K298e mini-
genes did not alter the ratio between 3R and 4R tau isoforms mRNAs 
(compared to K298e alone), indicating that the K298e mutation has 
a dominant effect on exon 10 splicing (lane 6). the quantification 
shown in b was the result of three different transfection experiments 
and was performed using the Image J program (http://imagej.nih.
gov/). c Rt-pCR of mRNA extracted from frontal cortex of the 
K298e mutation patient showed a clear increase in 4R tau mRNA 
expression and a decrease in 3R tau mRNA expression compared to 
mRNA extracted from an age-matched control subject
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antibodies. Cell nuclei were visualized with Hoechstbye 
(sigma Aldrich, 1:5,000) as previously reported [15]. Fluo-
rescence was visualized using a Leica tMDM 6000B fluo-
rescence microscope.
Immunoblotting
soluble tau was extracted with perchloric acid as described 
[8] from the frontal cortex of the proband, from the frontal 
Table 2  semi-quantitative assessment and regional distribution of neuronal loss, gliosis and tau pathology
Neuronal 
loss
Gliosis tau pathology
threads Dots Neuronal  
rings/crescents
Neuronal 
flame shaped
Neuronal 
globular
Neuronal 
diffuse
Oligodendroglial Astrocytic
Cortex
 Frontal ++ +++ +++ + +++ + ++ ++ + ++
 Motor + ++ +++ + +++ ++ + +++ + +
 temporal + + +++ + +++ + + ++ + ++
 parietal ++ +++ +++ + +++ + ++ ++ + ++
 Occipital − + ++ + + ++ + + − +
 Cingulate + ++ +++ + +++ + + +++ +
sub-cortical white matter
 Frontal N/A +++ ++ ++ N/A N/A N/A N/A +++ −
 Motor N/A +++ ++ + N/A N/A N/A N/A +++ −
 temporal N/A + ++ ++ N/A N/A N/A N/A +++ −
 parietal N/A +++ ++ ++ N/A N/A N/A N/A +++ −
 Occipital N/A ++ + + N/A N/A N/A N/A + −
 Cingulate N/A ++ ++ ++ N/A N/A N/A N/A +++ −
 Amygdala + +++ ++ +++ +++ + ++ +++ + ++
Hippocampus
 Dentate fascia −
(Dispersed)
+ ++ + ++ + − +++ − −
 CA4 +++ +++ +++ + + − − + + −
 CA3 +++ +++ +++ + − − − + + −
 CA2 − ++ +++ + − − + +++ − −
 CA1 + ++ +++ + + ++ + +++ + −
 subiculum + ++ +++ + + + ++ +++ + +
 entorhinal cortex + +++ +++ ++ +++ + + +++ + +
 transentorhinal cortex + +++ +++ ++ +++ − ++ +++ + +
Caudate ++ ++ +++ + +++ − ++ ++ + ++
putamen − ++ +++ + +++ − ++ + + ++
Globus pallidus − +++ ++ + + − + + +++ −
Meynert − ++ +++ ++ − − +++ +++ + +
thalamus − ++ +++ + − − + ++ +++ +
 subthalamic nucleus − ++ ++ + − − ++ ++ + −
Midbrain tegmentum − ++ ++ + + − + +++ + −
substantia nigra + ++ +++ + + − + +++ + −
Locus coeruleus + ++ + ++ − − − ++ − −
pontine tegmentum − ++ ++ ++ − − + +++ + −
pontine nuclei − ++ + +++ − − + ++ ++ −
Dorsal motor nucleus  
of vagus
− ++ + + − − + + − −
twelfth nerve nucleus − ++ + ++ − − − − + −
Inferior olive − ++ − +++ − − − − − +
Cerebellar purkinje cells + + − + − − − − − −
Cerebellar white matter N/A ++ − + N/A N/A N/A N/A − −
Dentate nucleus − + + + − − + + − −
N/A not applicable
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cortex of a patient with the I10+3 G>A intronic MAPT 
mutation [26] and from the frontal cortex of a control sub-
ject. Insoluble tau was extracted with sarkosyl from the 
frontal cortex of the proband, as described [9]. soluble 
and sarkosyl-insoluble tau proteins were dephosphorylated 
with 0.3 U/μl alkaline phosphatase from E. coli (sigma-
Aldrich) in 50 mM tris–HCl and 5 mM MgCl2 for 4 h at 
65 °C. the proteins were separated on 10 % sDs-pAGe 
and transferred onto immunobilon-p (Millipore, Bedford, 
MA, UsA). the membranes were incubated for 1 h with 
5 % milk w/v (premier International Foods, spalding, UK) 
in tBs/0.01 % tween-20. they were then probed with a 
polyclonal anti-human tau serum (Dako, Glostrup, Den-
mark, 1:1,000), followed by peroxidase-conjugated second-
ary antibody (Dako, 1:10,000). the blots were developed 
using Western lightning chemiluminescence reagent plus 
(perkin elmer, Waltham, MA, UsA).
Derivation and transdifferentiation of human fibroblasts
A skin biopsy was taken from the proband 2 h after death. 
It was cultured as an explant in DMeM supplemented with 
10 % FCs and 1 % penicillin/streptomycin for 2 weeks 
until fibroblasts started to appear. the fibroblasts were 
then expanded and transduced during their second passage 
as described previously [25] with the addition of delay-
ing doxycycline administration (=transgene activation) by 
5 days. As controls we used human embryonic fibroblasts 
(heFs) and human adult fibroblasts (hAFs) transduced in 
the same way.
Results
patient clinical data
In 2009, a 67-year-old lady was referred to the neurology 
service for investigation of progressive gait difficulties 
and non-fluent aphasia. she had previously developed a 
tremor of her right hand at the age of 48, which had been 
non-troubling. At the age of 65, the tremor became more 
severe and also spread to involve the left hand such that she 
had to give up writing and also driving. At that time her 
MMse score was 27/30 and a Ct brain scan revealed bilat-
eral cortical atrophy. speCt imaging by [(123) I] Fp-CIt 
(Datscan) was normal. Over the next 2 years, her condition 
progressed and she suffered a decline in her balance and 
mobility with initially recurrent falls and then progress-
ing such she could no longer stand or sit unaided. she also 
exhibited a decline in her speech with severe word finding 
difficulties. this was associated with marked anxiety and 
cognitive decline. she had now become dependent for all 
her daily living activities. During this time there had been 
no fluctuation in her condition and no history of visual hal-
lucinations. Her past medical history included sick sinus 
syndrome and she had been fitted with a cardiac pace-
maker. the family history was relevant as her father was 
diagnosed with Alzheimer’s disease in his 60 s and died at 
the age of 67. there were no other family members with 
dementia. she was a non-smoker and there was no history 
of alcohol excess.
significant examination findings included: an unreac-
tive facies and severe cognitive impairment, which pre-
vented completion of a full MMse. there was a paucity 
of speech and her speech was effortful. she was able to 
register three objects but could not recall any. she was 
poor at naming objects. she could perform a one-stage 
command but not three. she exhibited perseveration. she 
had prominent primitive reflexes including grasp reflexes 
and rooting response. In her limbs, she had a bilateral 
symmetrical myoclonic tremor (arms > legs), which was 
irregular and jerky. she had increased tone in all limbs 
with marked spasticity of her right arm. Her deep tendon 
reflexes were brisk (right > left) with down-going plantar 
responses.
Blood investigations, including treponemal serology and 
vasculitic screen, were unremarkable. A repeat Ct brain 
scan showed progression of the cerebral atrophy. CsF anal-
ysis was normal. eeG revealed intermittent slow waves, 
mainly in the right hemisphere, suggesting cortical dys-
function. Genetic analysis of MApt revealed a novel single 
nucleotide change from A>G (AAA to AAG) at codon 298 
in exon 10 which resulted in a change from Lys 298 to Glu 
in one allele. the proband’s condition progressed and she 
died in 2010.
Fig. 3  Neuropathological features in the anterior frontal cortex of the 
proband. there was mild superficial spongiosis (a), ballooned neu-
rons were identified in H&e stained sections (b) and were confirmed 
by αB crystallin immunohistochemistry (c). A proportion of neurons 
contained basophilic inclusions (d). tau-immunoreactive inclusions 
were abundant (e). High magnification revealed tau-positive dots and 
threads (f arrow and g arrow, respectively) and frequent neuronal 
inclusions with ring or crescent morphology (f), diffuse (g), flame-
shaped (h) or globular appearance (j). In the subcortical white mat-
ter tau-immunoreactive oligodendroglial inclusions and threads were 
abundant (k). All inclusion types showed strong immunoreactivity for 
4R tau isoforms (i), including structures resembling tufted astrocytes 
(m) and neuronal inclusions (n), while only a minority of inclusions 
could be identified using immunohistochemistry for 3R tau (l). there 
was strong immunoreactivity for p62 in a proportion of neuronal (o) 
and astrocytic inclusions (o inset). Many neuronal (p), astrocytic (q) 
and oligodendroglial inclusions (r) in addition to threads (r arrow) 
were argyrophilic as demonstrated using the Gallyas silver impreg-
nation method. a, b, d H&e; c αB crystallin immunohistochemistry; 
e–k phospho-tau immunohistochemistry (At8); i, m, n 4R tau immu-
nohistochemistry; l 3R tau immunohistochemistry; o p62 immuno-
histochemistry; p–r Gallyas silver impregnation. Bar in a represents 
100 μm in a, e; 50 μm in i, l; 25 μm in b, c, m–p; 10 μm in d, f–k, 
q, r
▸
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Microtubule assembly
Microtubule assembly assays were performed with recom-
binant wild-type or mutant tau proteins carrying the K298e 
mutation or the previously characterized p301s mutation. 
Both p301s and K298e recombinant proteins showed a 
reduced ability to promote microtubule assembly compared 
to wild-type tau (Fig. 1), suggesting that the K298e muta-
tion disrupts the ability of tau to interact with microtubules.
tau splicing
We next examined the effect of the K298e tau mutation 
on exon 10 alternative mRNA splicing in cultured cells. A 
minigene construct with A892>G mutation was engineered 
based on the previously described human tau minigene 
model [17]. Human NsCs were transiently transfected at 
day 20 of differentiation with mutant K298e or the wild-
type tau minigene, as described [1]. Untransfected human 
NsCs expressed a strong 3R tau isoform and a very weak 
4R tau band at the mRNA but not the protein levels as 
previously shown [15] (Fig. 2a, lane 1). When transfected 
with the empty vector or the wild-type tau minigene, the 
level of expression of 3R tau remained high. In contrast, 
transfection of the I10+3 mutation minigene (Fig. 2a, lane 
4) or the K298e mutant minigene (Fig. 2a, lane 5) altered 
the ratio between 3R and 4R tau isoforms in favour of 4R 
tau, indicating that the two mutations strongly reduced 
the splicing out of exon 10. Co-transfection of the wild-
type minigene and the K298e minigene still increased 
the amount of transcripts with exon 10, indicating that 
the K298e mutation had a dominant effect on the splic-
ing of exon 10 (Fig. 2a, lane 6). Figure 2b shows a quan-
tification of tau isoform mRNA levels in human NsCs in 
three different experiments for each line. the effect of the 
K298e on exon 10 splicing was confirmed by Rt-pCR of 
RNA extracted from the patient’s brain. A clear increase 
of the 4R tau band was observed compared to the Rt-pCR 
of RNA extracted from the cortex of a control subject 
(Fig. 2c).
Brain post-mortem study
the left half of the brain weighed 513 g. external examina-
tion and coronal slices showed severe atrophy of the frontal 
lobe, including the motor strip, and the anterior temporal 
lobe, while the parietal and posterior temporal lobes were 
less severely affected and there was good preservation of 
the occipital lobe. there was severe dilatation of the fron-
tal and temporal horns of the lateral ventricle. the corti-
cal ribbon was thin throughout the frontal lobe and in all 
three temporal gyri anteriorly with patchy thinning in the 
parietal lobe and in the second and third temporal gyri 
posteriorly. there was atrophy of the caudate nucleus and 
thalamus with preservation of the putamen, globus pallidus 
and subthalamic nucleus. the hippocampus and amygdala 
were severely atrophic. Both the substantia nigra and the 
locus coeruleus were pale. Medulla and cerebellum were 
unremarkable.
Histology and immunohistochemistry
Immunohistochemistry showed widespread neuronal loss 
and gliosis with abundant deposition of hyperphosphoryl-
ated tau in neurons and glia. the semiquantitative assess-
ment of these features in different brain regions is detailed 
in table 2.
In addition to cortical thinning, gliosis and mild superfi-
cial spongiosis in the frontal, temporal and parietal cortices, 
a number of ballooned neurons were observed, they were 
particularly prominent in the cingulate gyrus (Fig. 3a–c). 
Neuronal loss was most severe in the frontal and parietal 
cortices, the caudate nucleus and in the CA3 and CA4 sub-
regions of the hippocampus (Fig. 4a). Although neuronal 
loss was not marked in the dentate fascia of the hippocam-
pus, there was dispersion of the granule cell layer (Fig. 4a). 
poorly defined basophilic inclusions were evident in a 
proportion of neurons in haematoxylin- and eosin-stained 
sections (Fig. 3d). tau immunohistochemistry revealed 
extensive neuronal and glial deposition of phosphorylated 
tau (At8, epitope phosphoser202 and phosphothr205) 
(Figs. 3e–k, 4c–h). Neuronal inclusions of various types 
were observed: crescentic or ring-like perinuclear inclu-
sions; diffuse cytoplasmic staining, sometimes also con-
taining fine filaments; flame-shaped inclusions and globu-
lar inclusions. the former were particularly marked in the 
small neurons of the superficial cortical laminae (Fig. 3f–j). 
Astrocytic tau pathology was observed with morphological 
features similar to tufted astrocytes (Fig. 3m, o, q). In white 
matter there were frequent tau-immunoreactive oligoden-
droglial inclusions, numerous threads and dots (Fig. 3k). 
All of these structures were immunoreactive for 4R tau and 
astrocytic pathology was most clearly visible in this prepa-
ration (Figs. 3l, m, n; 4b). 3R tau was also detected in a 
proportion of inclusions, predominantly neuronal, using 
immunohistochemistry, but immunoreactivity was much 
more restricted than that of 4R tau (Fig. 3l). At100-posi-
tive staining recognized a proportion of neuronal inclu-
sion and threads. p62 immunohistochemistry highlighted 
abnormal astrocytes, some of the neuronal inclusions and 
a proportion of oligodendroglial inclusions in white matter 
(Fig. 3o). Ubiquitin immunohistochemistry revealed weak 
immunoreactive inclusions mostly with a morphology com-
patible with astrocytic inclusions. Gallyas silver staining 
demonstrated a proportion of neuronal, astrocytic and oli-
godendroglial inclusions, in addition to some of the thread 
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pathology indicating fibrillar tau deposition (Fig. 3p–r). 
there was no tDp-43 or Aβ pathology in neocortical 
regions or the hippocampus. No α-synuclein pathology in 
the form of Lewy bodies, Lewy neurites or glial cytoplas-
mic inclusions was found in brainstem, limbic or cortical 
regions.
Fig. 4  Neuropathological features in the hippocampus and subcor-
tical nuclei of the proband. In the hippocampal formation there was 
marked neuronal loss in the CA4 subregion and dispersion of the 
granule cells of the dentate fascia (a) and tau immunohistochemis-
try showed widespread neuronal immunoreactivity, often diffuse in 
character, and sometimes with additional filamentous inclusions (b, 
subiculum). tau-immunoreactive inclusions were widespread in sub-
cortical structures, including: caudate nucleus (c), globus pallidus 
(d), subthalamic nucleus (e), substantia nigra (f), pontine nuclei (g) 
and dentate nucleus (h). a H&e; b 4R tau immunohistochemistry; 
c–h phospho-tau immunohistochemistry (At8). Bar in a represents 
250 μm in a; 50 μm in c–h; 25 μm in b
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Immunoblotting
to measure the level of expression of tau isoforms, solu-
ble tau was extracted with perchloric acid from the frontal 
cortex of a patient with the I10+3 mutation, normal adult 
human brain and the frontal cortex of the proband with 
the K298e mutation. All six tau isoforms were expressed 
in the normal, I10+3 and K298e tau mutant brains 
(Fig. 5a); however, in the K298e case the 4R tau isoforms 
1N4R appeared increased and the 3R tau isoforms 1N3R 
decreased (Fig. 5a). A slight increase in the 0N4R tau iso-
form could also be observed in the K298e case. these data 
showed and confirmed that tau pathology in the frontal 
cortex had a high prevalence of 4R tau isoforms. sarko-
syl-insoluble tau extraction from the frontal cortex of the 
proband with the K298e MAPT mutation confirmed that 
4R tau was the major component, although some 3R tau 
was also present (Fig. 5b). sarkosyl-insoluble tau extracted 
from the brain of the I10+3 case, where filaments had been 
shown to contain 4R tau, is shown for comparison.
tau isoforms expression in K298e-induced neurons
Direct conversion of human fibroblasts into neurons is 
of potential clinical utility and of interest for neurologi-
cal disease modelling, as well as for cell therapeutics [3]. 
A skin biopsy was taken from the patient with the K298e 
mutation 2 h post-mortem and fibroblasts were derived. 
these were then expanded and converted into iNs, as pre-
viously described [24, 25]. As controls, human embryonic 
fibroblasts (heFs) and human adult fibroblasts (hAFs) 
were converted into neurons following an identical pro-
tocol. two weeks after transgene activation, induced neu-
rons started to appear in both controls and K298e cells, 
but tau was not detected (data not shown). thirty days 
after transgene activation, while iNs obtained from human 
embryonic fibroblasts (heF-iN) expressed only the 3R tau 
isoform, iNs with the K298e mutation (iN-K298e) and iNs 
from hAF (hA-iN) expressed both 3R and 4R tau (Fig. 6a). 
Fifty-three days after transgene activation, the level of 
expression of both tau isoforms in the iN-K298e did not 
increase (Fig. 6b) and was comparable to the level of tau 
observed in hAF-iNs. However, heF-iNs still expressed 
only 3R tau 53 days after transduction (Fig. 6b). the lim-
ited availability of fibroblasts and differentiated neurons 
did not allow for biochemical studies or more indepth 
analyses.
Discussion
We report a novel missense mutation in MAPT in a 67-year-
old lady who was referred with dementia and non-fluent 
aphasia. Genetic analysis revealed the presence of a K298e 
missense mutation in exon 10 in one of her alleles.
Missense mutations in MAPT have mainly been identi-
fied in the coding region, with a cluster of mutations close 
to the 5′ splice site of exon 10. exon 10 mutations and 
intronic mutations immediately downstream of the 5′ splice 
site of exon 10 can modulate the splicing of tau pre-mRNA, 
which leads to an over-representation of 4R tau. However, 
some exon 10 mutations, including p301L and p301s, only 
have effects at the protein level [13, 14, 20]. the region of 
exon 10, which contains Lys 298 has been shown to contain 
Fig. 5  soluble and insoluble tau protein from human brain. a tau iso-
forms extracted from frontal cortex of brains of the patient with the 
K298e MApt mutation, a patient with the I10+3 G>A (+3) MApt 
mutation and a control subject before (−) and after (Ap) dephospho-
rylation with alkaline phosphatase (Ap). the pattern of tau isoforms 
extracted from the frontal cortex of the patient with the K298e muta-
tion shows that this mutation induces an increase in 1N4R tau isoform 
expression, with a decrease in 1N3R tau isoform. A slight increase can 
be also observed for the 0N4R tau isoform. As comparison extracts 
from cortex of a patient with the I10+3 G>A (+3) MApt mutation 
and a control subject before and after Ap treatment are also shown. 
Recombinant human tau (rtau) isoforms were run as a control. Molec-
ular weight markers (Mw). b sarkosyl-insoluble tau from the frontal 
cortex of the patient with the K298e tau mutation before (−) and after 
(Ap) dephosphorylation with alkaline phosphatase and from frontal 
cortex of a patient with the I10+3 G>A (+3) mutation. the immu-
noblot shows that insoluble tau from frontal cortex contained mainly 
4R tau isoforms although some 3R tau appears also to be present in 
the K298e case. the extra bands in the +3 extract could be degrada-
tion products in a tissue that also contained some Alzheimer type tau 
changes. Recombinant tau isoforms (rtau) were run in parallel to the 
samples. Molecular weight markers (Mw)
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Fig. 6  tau isoform expres-
sion in human K298e-derived 
neurons. a 3R and 4R tau 
isoform expression in induced 
neurons with K298e mutation 
(iN-K298e), in induced neurons 
from human adult fibroblasts 
(hAF-iN) and in induced 
neurons from human embryonic 
fibroblasts (heF-iN) at 30 days 
after transgene activation. b 3R 
and 4R tau isoform expression 
in iN-K298e, hAF-iN and heF-
iN at 53 days post-transgene 
activation and beginning of 
differentiation
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an exonic splice suppressor (ess) that negatively regu-
lates the splicing of exon 10 [4, 5]. Indeed, mutations at 
codon 296, in the same ess, have been described, includ-
ing N296H, N296N, and ΔN296 [16, 23, 27]. Interestingly, 
N296N and N296H lead to an increase in 4R tau mRNA, 
while mutation ΔN296 has no effect on alternative mRNA 
splicing of MAPT [11, 28]. In contrast, the ΔN296 muta-
tion effected a marked reduction in microtubule assem-
bly while the N296H mutation also significantly reduced 
microtubule assembly, but less so ΔN296 [12]. the K298e 
mutation similar to the N296H, affects both tau microtu-
bule assembly and 4R tau expression.
We performed a microtubule assembly assay using 
mutant K298e recombinant tau protein. the K298e muta-
tion reduced the ability of tau to promote microtubule 
assembly compared to wild-type tau. We next evaluated 
the effects of the K298e mutation at the mRNA level and 
performed minigene transfection experiments. In human 
NsCs, the transfection of the tau minigene expressing the 
K298e mutation induced the overexpression of 4R tau 
(Fig. 2a). Our in vitro data suggest that the K298e muta-
tion induces the overproduction of mutant 4R tau, which 
is impaired in its ability to interact with microtubules. the 
pathogenicity of the K298e mutation was also confirmed 
by neuropathological analysis of the post-mortem brain, 
which showed severe atrophy of frontal and anterior tem-
poral lobe, as well as of caudate nucleus and thalamus. 
Neuronal loss and gliosis confirmed that the pathology was 
widespread in frontal and parietal cortices, with abundant 
deposition of hyperphosphorylated tau in neurons and glia, 
reminiscent of progressive supranuclear palsy [18]. tau 
pathology consisted mainly of 4R tau. Biochemical anal-
ysis of soluble tau showed an increase in 4R and a slight 
decrease in 3R tau. In sarkosyl-insoluble tau from frontal 
cortex of the patient, as in progressive supranuclear palsy, 
the 64 and 68 kDa bands contained mainly 4R tau, although 
a small amount of 3R tau was also present (Fig. 5).
Direct conversion of patient skin fibroblasts into neurons 
was performed to test whether they express tau isoforms 
and could show the increase in 4R tau. the skin biopsy was 
collected 2 h post-mortem; it was not possible to obtain 
induced pluripotent stem cells (ipsCs) from the biopsy-
derived fibroblasts, although several attempts were made 
by various laboratories. therefore, we decided to opt for 
direct conversion of fibroblasts into induced neurons (iNs). 
Although this approach gave positive results and neurons 
were produced, they were not in sufficient number to allow 
biochemical characterization of their tau isoforms. to our 
knowledge, this is the first study showing tau protein in iNs 
derived from fibroblasts of a patient with a MAPT muta-
tion collected postmortem. Our analysis has given insight 
into the study of patient-derived iNs, i.e., that the type of 
controls used is critical for the evaluation of neuronal 
phenotype, as far as tau is concerned. We observed a differ-
ence in the time course of tau isoform expression between 
iNs from the proband and iNs from embryonic fibroblasts 
initially available and used as control, this was not present 
when comparing iNs from fibroblasts of the proband and 
of an age-matched control. this suggests that induced neu-
rons obtained from embryonic fibroblasts can take longer 
to mature compared to those obtained from adult human 
fibroblasts and are not suitable as control.
In conclusion, we report a novel K298e tau mutation 
in a patient with frontotemporal dementia. the mutation 
affected both tau microtubule assembly and tau mRNA 
splicing with an increase in 4R tau. therefore, the K298e 
mutation becomes another member of a small group of 
exon 10 mutations, which confer pathogenicity through 
effects at both the RNA and the protein level.
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